Skip to content
lifestyle.phenomena.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Jade Biosciences
Jade Biosciences Announces Proposed Underwritten Public Offering
June 3, 2026
Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy
June 1, 2026
Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy
May 29, 2026
Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody
May 26, 2026
Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy
May 26, 2026
Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 7, 2026
Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 23, 2026
Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer
April 22, 2026
Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 6, 2026
Jade Biosciences to Participate in Upcoming Conferences
February 12, 2026